Christopher Mutz is HEAD OF RARE DISEASE at ANI PHARMACEUTICALS INC (ANIP). They have made 8 open-market trades across 1 company since 2023, most recently 2026-03-13.
CIK 0001846487
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANIP | 91,309 | $6.5M |
Shares reported on the most recent Form 4, priced at the 2026-03-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANIP | SELL | 2026-03-13 | 2026-03-13 | $71.64 | $227K | +4.7% | +10.7% | +15.5% |
| ANIP | SELL | 2026-03-06 | 2026-03-10 | $74.19 | $425K | -1.8% | +5.4% | +5.4% |
| ANIP | SELL · 10b5-1 | 2026-03-02 | 2026-03-04 | $74.00 | $31K | -4.5% | +2.1% | -1.2% |
| ANIP | SELL · 10b5-1 | 2026-02-20 | 2026-02-23 | $78.02 | $415K | +0.3% | -1.7% | +7.8% |
| ANIP | SELL | 2026-02-12 | 2026-02-17 | $76.55 | $538K | -6.3% | -5.1% | +0.4% |
| ANIP | SELL | 2025-05-14 | 2025-05-15 | $60.45 | $242K | -2.9% | +8.0% | +49.1% |
| ANIP | SELL | 2024-11-15 | 2024-11-18 | $57.70 | $375K | +5.1% | -1.1% | +7.8% |
| ANIP | SELL | 2024-05-21 | 2024-05-22 | $61.61 | $123K | +5.1% | -5.0% | -0.7% |
| ANIP | SELL | 2024-03-05 | 2024-03-06 | $66.00 | $330K | +1.6% | +1.6% | -2.7% |
| ANIP | SELL | 2023-11-10 | 2023-11-13 | $52.47 | $157K | -1.7% | -0.3% | +8.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.